Rozlišování různých typů dysplazie v Barrettově jícnu - první krok k harmonizaci gradingu

1. Riddell RH, Goldman H, Ransohoff DF, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 1983; 14(11): 931-968.

2. Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol 2001; 32(4): 368-378.

3. Reid BJ, Haggitt RC, Rubin CE, et al. Observer variation in the diagnosis of dysplasia in Barrett’s esophagus. Hum Pathol 1988; 19(2): 166-178.

4. Odze RD. Diagnosis and grading of dysplasia in Barrett’s oesophagus. J Clin Pathol 2006; 59(10): 1029-1038.

5. Vieth M, Stolte M. Pathology of early upper GI cancers. Best Pract Res Clin Gastroenterol 2005; 19(6): 857-869.

6. Downs-Kelly E, Mendelin JE, Bennett AE, et al. Poor interobserver agreement in the distinction of high-grade dysplasia and adenocarcinoma in pretreatment Barrett’s esophagus biopsies. AmJ Gastroenterol 2008; 103(9): 2333-2340; quiz 2341.

7. Lauwers GY, Shimizu M, Correa P, et al. Evaluation of gastric biopsies for neoplasia: differences between Japanese and Western pathologists. Am J Surg Pathol 1999; 23(5): 511-518.

8. Sakurai U, Lauwers GY, Vieth M, et al. Gastric high-grade dysplasia can be associated with submucosal invasion: evaluation of its prevalence in a series of 121 endoscopically resected specimens. Am J Surg Pathol 2014; 38(11): 1545-1550.

9. Schlemper RJ, Itabashi M, Kato Y, et al. Differences in diagnostic criteria for gastric carcinoma between Japanese and western pathologists. Lancet 1997; 349(9067): 1725-1729.

10. Schlemper RJ, Riddell RH, Kato Y, et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000; 47(2): 251-255.

11. Vieth M, Riddell RH, Montgomery EA. High-grade dysplasia versus carcinoma: east is east and west is west, but does it need to be that way? Am J Surg Pathol 2014; 38(11): 1453-1456.

12. Watanabe H, Jass J, Sobin L, eds. Histologic Typing of Oesophageal and Gastric Tumours, page 20. Berlin: Springer-Verlag; 1990.

13. Canto MI, Anandasabapathy S, Brugge W, et al. In vivo endomicroscopy improves detection of Barrett’s esophagus-related neoplasia: a multicenter international randomized controlled trial (with video). Gastrointest Endosc 2014; 79(2): 211-221.

14. Dunbar KB, Canto MI. Confocal laser endomicroscopy in Barrett’s esophagus and endoscopically inapparent Barrett’s neoplasia: a prospective, randomized, double-blind, controlled, crossover trial. Gastrointest Endosc 2010; 72(3): 668.

15. Manner H, Pech O, Heldmann Y, et al. The frequency of lymph node metastasis in early-stage adenocarcinoma of the esophagus with incipient submucosal invasion (pT1b sm1) depending on histological risk patterns. Surgical endoscopy 2015; 29(7): 1888-1896.

16. Pech O, May A, Manner H, et al. Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus. Gastroenterology 2014; 146(3): 652-660.

17. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med 2009; 360(22): 2277-2288.

18. American Gastroenterological Association, Spechler SJ, Sharma P, et al. American Gastroenterological Association medical position statement on the management of Barrett’s esophagus. Gastroenterology 2011; 140(3): 1084-1091.

19. Bennett C, Moayyedi P, Corley DA, et al. BOB CAT: a large-scale review and delphi consensus for management of Barrett’s esophagus with no dysplasia, indefinite for, or low-grade dysplasia. Am J Gastroenterol 2015; 110(6): 662-682.

20. Epstein JI, Allsbrook WC, Jr., Amin MB, et al. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. The Am J Surg Pathol 2005; 29(9): 1228-1242.

21. Stoler MH. New Bethesda terminology and evidence-based management guidelines for cervical cytology findings. JAMA 2002; 287(16): 2140-2141.

22. Riddell RH, Odze RD. Definition of Barrett’s esophagus: time for a rethink--is intestinal metaplasia dead? Am J Gastroenterol 2009; 104(10): 2588-2594.

23. Coco DP, Goldblum JR, Hornick JL, et al. Interobserver variability in the diagnosis of crypt dysplasia in Barrett esophagus. Am J Surg Pathol 2011; 35(1): 45-54.

24. Lomo LC, Blount PL, Sanchez CA, et al. Crypt dysplasia with surface maturation: a clinical, pathologic, and molecular study of a Barrett’s esophagus cohort. Am J Surg Pathol 2006; 30(4): 423-435.

25. Mahajan D, Bennett AE, Liu X, et al. Grading of gastric foveolar-type dysplasia in Barrett’s esophagus. Mod Pathol 2010; 23(1): 1-11.

26. Naini BV, Chak A, Ali MA, et al. Barrett’s oesophagus diagnostic criteria: endoscopy and histology. Best Pract Res Clin Gastroenterol 2015; 29(1): 77-96.

27. Odze RD. What the gastroenterologist needs to know about the histology of Barrett’s esophagus. Curr Opin Gastroenterol 2011; 27(4): 389-396.

28. Patil DT, Bennett AE, Mahajan D, et al. Distinguishing Barrett gastric foveolar dysplasia from reactive cardiac mucosa in gastroesophageal reflux disease. Hum Pathol 2013; 44(6): 1146-1153.

29. Rucker-Schmidt RL, Sanchez CA, Blount PL, et al. Nonadenomatous dysplasia in barrett esophagus: a clinical, pathologic, and DNA content flow cytometric study. Am J Surg Pathol 2009; 33(6): 886-893.

30. Sangle NA, Taylor SL, Emond MJ, et al. Overdiagnosis of high-grade dysplasia in Barrett’s esophagus: a multicenter, international study. Mod Pathol 2015; 28(6): 758-765.

31. Kaneshiro DK, Post JC, Rybicki L, et al. Clinical significance of the duplicated muscularis mucosae in Barrett esophagus-related superficial adenocarcinoma. Am J Surg Pathol 2011; 35(5): 697-700.

32. Westerterp M, Koppert LB, Buskens CJ, et al. Outcome of surgical treatment for early adenocarcinoma of the esophagus or gastro-esophageal junction. Virchows Arch 2005; 446(5): 497-504.

33. Abraham SC, Krasinskas AM, Correa AM, et al. Duplication of the muscularis mucosae in Barrett esophagus: an underrecognized feature and its implication for staging of adenocarcinoma. Am J Surg Pathol 2007; 31(11): 1719-1725.

34. Estrella JS, Hofstetter WL, Correa AM, et al. Duplicated muscularis mucosae invasion has similar risk of lymph node metastasis and recurrence-free survival as intramucosal esophageal adenocarcinoma. Am J Surg Pathol 2011; 35(7): 1045-1053.

35. Hahn HP, Shahsafaei A, Odze RD. Vascular and lymphatic properties of the superficial and deep lamina propria in Barrett esophagus. Am J Surg Pathol 2008; 32(10): 1454-1461.

36. Lewis JT, Wang KK, Abraham SC. Muscularis mucosae duplication and the musculo-fibrous anomaly in endoscopic mucosal resections for barrett esophagus: implications for staging of adenocarcinoma. Am J Surg Pathol 2008; 32(4): 566-571.

37. Mino-Kenudson M, Hull MJ, Brown I, et al. EMR for Barrett’s esophagus-related superficial neoplasms offers better diagnostic reproducibility than mucosal biopsy. Gastrointest Endosc 2007; 66(4): 660-666.

38. Ormsby AH, Petras RE, Henricks WH, et al. Observer variation in the diagnosis of superficial oesophageal adenocarcinoma. Gut 2002; 51(5): 671-676.

39. Hahn HP, Blount PL, Ayub K, et al. Intestinal differentiation in metaplastic, nongoblet columnar epithelium in the esophagus. Am J Surg Pathol 2009; 33(7): 1006-1015.

40. Kushima R, Vieth M, Mukaisho K, et al. Pyloric gland adenoma arising in Barrett’s esophagus with mucin immunohistochemical and molecular cytogenetic evaluation. Virchows Arch 2005; 446(5): 537-541.

41. Vieth M, Montgomery EA. Some observations on pyloric gland adenoma: an uncommon and long ignored entity! J Clin Pathol 2014; 67(10): 883-890.

42. Glickman JN, Blount PL, Sanchez CA, et al. Mucin core polypeptide expression in the progression of neoplasia in Barrett’s esophagus. Hum Pathol 2006; 37(10): 1304-1315.

43. Abraham SC. Fundic gland polyps: common and occasionally problematic lesions. Gastroenterol Hepatol (NY) 2010; 6(1): 48-51.

44. Abraham SC, Montgomery EA, Singh VK, et al. Gastric adenomas: intestinal-type and gastric-type adenomas differ in the risk of adenocarcinoma and presence of background mucosal pathology. Am J Surg Pathol 2002; 26(10): 1276-1285.

45. Abraham SC, Park SJ, Lee JH, et al. Genetic alterations in gastric adenomas of intestinal and foveolar phenotypes. Mod Pathol 2003; 16(8): 786-795.

46. Abraham SC, Park SJ, Mugartegui L, et al. Sporadic fundic gland polyps with epithelial dysplasia : evidence for preferential targeting for mutations in the adenomatous polyposis coli gene. Am J Pathol 2002; 161(5): 1735-1742.

47. Singhi AD, Lazenby AJ, Montgomery EA. Gastric adenocarcinoma with chief cell differentiation: a proposal for reclassification as oxyntic gland polyp/adenoma. Am J Surg Pathol 2012; 36(7): 1030-1035.

48. Ueyama H, Yao T, Nakashima Y, et al. Gastric adenocarcinoma of fundic gland type (chief cell predominant type): proposal for a new entity of gastric adenocarcinoma. Am J Surg Pathol 2010; 34(7): 609-619.

49. Srivastava A, Sanchez C, Cowan D, et al. Foveolar and serrated dysplasia are rare high-risk lesions in Barrett’s esophagus: a prospective outcome analysis of 214 patients. Hum Pathol 2010; 23(2): 742A.

50. Torlakovic EE, Gomez JD, Driman DK, et al. Sessile serrated adenoma (SSA) vs. traditional serrated adenoma (TSA). Am J Surg Pathol 2008; 32(1): 21-29.

51. Ngamruengphong S, Wolfsen HC, Wallace MB. Survival of patients with superficial esophageal adenocarcinoma after endoscopic treatment vs surgery. Clin Gastroenterol Hepatol 2013; 11(11): 1424-1429.

52. Canto MI, Shin EJ, Khashab MA, et al. Safety and efficacy of carbon dioxide cryotherapy for treatment of neoplastic Barrett’s esophagus. Endoscopy 2015; 47(7): 582-589.

53. Tsukashita S, Kushima R, Bamba M, Sugihara H, Hattori T. MUC gene expression and histogenesis of adenocarcinoma of the stomach. Int J Cancer 2001; 94(2): 166-170.

54. Martínek J, Falt P, Gregar J, et al. Guidelines of the Czech gastroenterological society –⁠ endoscopic treatment of Barrett’s esophagus and early esophageal neoplasia. Gastroent Hepatol 2013; 67(6): 479-487.